openPR Logo
Press release

Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

07-14-2020 05:04 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares over potential securities laws violations.

An investigation for investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares over potential securities laws violations.

An investigation was announced concerning potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.

Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Plano, TX based Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Reata Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $53.58 million in 2018 to $26.51 million in 2019, and that its Net Loss increased from $80.54 million in 2018 to $290.17 million in 2019.

Shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) declined from $257.96 per share in February 2020 to as low as $113.01 per share on March 23, 2020.

On July 13, 2020, NASDAQ: RETA shares closed at $153.03 per share.

Those who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) here

News-ID: 2089942 • Views: 776

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of Odonate Therapeutics, Inc. (NASDAQ: ODT …
An investor, who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT), filed a lawsuit over alleged Securities Laws violations by Odonate Therapeutics, Inc. Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 16, 2020. NASDAQ: ODT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Diego, CA based Odonate Therapeutics,
Investigation announced for Investors in NASDAQ: PINC over possible Wrongdoing a …
An investigation on behalf of investors in shares of Premier, Inc. (NASDAQ: PINC) was announced over potential breaches of fiduciary duties by certain officers and directors at Premier, Inc. Investors who purchased shares of Premier, Inc. (NASDAQ: PINC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Premier, Inc. directors breached their fiduciary duties and
Deadline on October 9th coming up in Lawsuit for Investors in shares of MEI Phar …
A deadline is coming up on October 9, 2020 in the lawsuit filed for certain investors of MEI Pharma, Inc. (NASDAQ: MEIP) over alleged securities laws violations by MEI Pharma, Inc. Investors who purchased shares of MEI Pharma, Inc. (NASDAQ: MEIP) have certain options and there are strict and short deadlines running. Deadline: October 9, 2020. NASDAQ: MEIP stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Casper Sleep Inc. ( …
An investigation on behalf of current long-term investors in shares of Casper Sleep Inc. (NYSE: CSPR) concerning potential breaches of fiduciary duties by certain directors and officers of Casper Sleep Inc. was announced. Investors who are current long term investors in Casper Sleep Inc. (NYSE: CSPR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for

All 5 Releases


More Releases for Reata

Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. Download the sample report @ https://www.pharmaproff.com/request-sample/1078 The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in
Mitochondrial Myopathies Market 2018: Key Players- Reata Pharmaceuticals, Inc., …
An expert on premium research reports, Market Research Future has added a report titled "Global Mitochondrial Myopathies Market 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.    Market scenario: The Mitochondrial Myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing
Diabetic Nephropathy market 2020 | Pfizer, Inc., Merck & Co., Inc., Sanofi, Reat …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the
Diabetic Nephropathy market 2020 | Novartis AG, Pfizer, Inc., Merck & Co., Inc., …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the
Nuclear factor-kappa B Inhibitors Therapeutics - Pipeline Analysis Alkermes, Rea …
The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation. Download report sample at: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis/report-sample *Various
Mitochondrial Myopathies Market 2018 – Major Competitors: are Reata Pharmaceut …
Mitochondrial myopathy is an umbrella term for rare genetic diseases due to defective mitochondria in cells which results in inability of the mitochondria to consume normal levels of oxygen and produce energy. The disease manifests itself from infancy to adulthood. Although there is no cure for the disease, there have been some research initiatives from pharmaceutical companies. For example, the drug Bendavia of Stealth BioTherapeutics Inc. is undergoing Phase 2 clinical